Spinal Cord Injury – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Spinal Cord Injury – Pipeline Review, H2 2019’, provides an overview of the Spinal Cord Injury pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Spinal Cord Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Spinal Cord Injury and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Spinal Cord Injury

– The report reviews pipeline therapeutics for Spinal Cord Injury by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Spinal Cord Injury therapeutics and enlists all their major and minor projects

– The report assesses Spinal Cord Injury therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Spinal Cord Injury”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Spinal Cord Injury

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Spinal Cord Injury pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“AbbVie Inc

Algiax Pharmaceuticals GmbH

Aposcience AG

Athersys Inc

BioAxone BioSciences Inc

Cellatoz Therapeutics Inc

CellCure

CSL Ltd

CSPC Pharmaceutical Group Ltd

Daewoong Pharmaceutical Co Ltd

EUSOL Biotech Co Ltd

Fortuna Fix Inc

GABA Therapeutics Inc

GNT Pharma Co Ltd

Helixmith Co Ltd

Hemostemix Inc

Hibernaid Inc

Histocell SL

Hope Biosciences LLC

K-Stemcell Co Ltd

Kringle Pharma Inc

Lineage Cell Therapeutics Inc

Mapreg SAS

Mitsubishi Tanabe Pharma Corp

NervGen Pharma Corp

NeuExcell Therapeutics Inc

Neuronax SAS

Neuroplast BV

New World Laboratories Inc

Novago Therapeutics AG

Novartis AG

Novoron Bioscience Inc

NuNerve Pty Ltd

PharmatrophiX Inc

Pharmazz Inc

Pharmicell Co Ltd

PixarBio Corp

Q Therapeutics Inc

Radikal Therapeutics Inc

RDD Pharma Ltd

ReNetX Bio

RespireRx Pharmaceuticals Inc

SanBio Inc

Seneca Biopharma Inc

StemCyte Inc

Stemedica Cell Technologies Inc

Sumitomo Dainippon Pharma Co Ltd

TechnoPhage SA

Tumorend LLC

Xcelthera INC

ZyVersa Therapeutics Inc”

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Spinal Cord Injury Overview 6

Spinal Cord Injury Therapeutics Development 7

Spinal Cord Injury Therapeutics Assessment 18

Spinal Cord Injury Companies Involved in Therapeutics Development 30

Spinal Cord Injury Drug Profiles 43

Spinal Cord Injury Dormant Projects 176

Spinal Cord Injury Discontinued Products 180

Spinal Cord Injury Product Development Milestones 181

Appendix 191

List of Tables

“List of Tables

Number of Products under Development for Spinal Cord Injury, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Spinal Cord Injury – Pipeline by AbbVie Inc, H2 2019

Spinal Cord Injury – Pipeline by Algiax Pharmaceuticals GmbH, H2 2019

Spinal Cord Injury – Pipeline by Aposcience AG, H2 2019

Spinal Cord Injury – Pipeline by Athersys Inc, H2 2019

Spinal Cord Injury – Pipeline by BioAxone BioSciences Inc, H2 2019

Spinal Cord Injury – Pipeline by Cellatoz Therapeutics Inc, H2 2019

Spinal Cord Injury – Pipeline by CellCure, H2 2019

Spinal Cord Injury – Pipeline by CSL Ltd, H2 2019

Spinal Cord Injury – Pipeline by CSPC Pharmaceutical Group Ltd, H2 2019

Spinal Cord Injury – Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2019

Spinal Cord Injury – Pipeline by EUSOL Biotech Co Ltd, H2 2019

Spinal Cord Injury – Pipeline by Fortuna Fix Inc, H2 2019

Spinal Cord Injury – Pipeline by GABA Therapeutics Inc, H2 2019

Spinal Cord Injury – Pipeline by GNT Pharma Co Ltd, H2 2019

Spinal Cord Injury – Pipeline by Helixmith Co Ltd, H2 2019

Spinal Cord Injury – Pipeline by Hemostemix Inc, H2 2019

Spinal Cord Injury – Pipeline by Hibernaid Inc, H2 2019

Spinal Cord Injury – Pipeline by Histocell SL, H2 2019

Spinal Cord Injury – Pipeline by Hope Biosciences LLC, H2 2019

Spinal Cord Injury – Pipeline by K-Stemcell Co Ltd, H2 2019

Spinal Cord Injury – Pipeline by Kringle Pharma Inc, H2 2019

Spinal Cord Injury – Pipeline by Lineage Cell Therapeutics Inc, H2 2019

Spinal Cord Injury – Pipeline by Mapreg SAS, H2 2019

Spinal Cord Injury – Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2019

Spinal Cord Injury – Pipeline by NervGen Pharma Corp, H2 2019

Spinal Cord Injury – Pipeline by NeuExcell Therapeutics Inc, H2 2019

Spinal Cord Injury – Pipeline by Neuronax SAS, H2 2019

Spinal Cord Injury – Pipeline by Neuroplast BV, H2 2019

Spinal Cord Injury – Pipeline by New World Laboratories Inc, H2 2019

Spinal Cord Injury – Pipeline by Novago Therapeutics AG, H2 2019

Spinal Cord Injury – Pipeline by Novartis AG, H2 2019

Spinal Cord Injury – Pipeline by Novoron Bioscience Inc, H2 2019

Spinal Cord Injury – Pipeline by NuNerve Pty Ltd, H2 2019

Spinal Cord Injury – Pipeline by PharmatrophiX Inc, H2 2019

Spinal Cord Injury – Pipeline by Pharmazz Inc, H2 2019

Spinal Cord Injury – Pipeline by Pharmicell Co Ltd, H2 2019

Spinal Cord Injury – Pipeline by PixarBio Corp, H2 2019

Spinal Cord Injury – Pipeline by Q Therapeutics Inc, H2 2019

Spinal Cord Injury – Pipeline by Radikal Therapeutics Inc, H2 2019

Spinal Cord Injury – Pipeline by RDD Pharma Ltd, H2 2019

Spinal Cord Injury – Pipeline by ReNetX Bio, H2 2019

Spinal Cord Injury – Pipeline by RespireRx Pharmaceuticals Inc, H2 2019

Spinal Cord Injury – Pipeline by SanBio Inc, H2 2019

Spinal Cord Injury – Pipeline by Seneca Biopharma Inc, H2 2019

Spinal Cord Injury – Pipeline by StemCyte Inc, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports